Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 27, 2016

Primary Completion Date

July 21, 2020

Study Completion Date

July 21, 2020

Conditions
Solid TumorsHematological Malignancies
Interventions
DRUG

Belinostat IV

"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."

Trial Locations (3)

44718

Gabrail Cancer Center Research, Canton

90404

John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica

90603

The Oncology Institute of Hope and Innovation, Whittier

All Listed Sponsors
collaborator

Axis Clinicals Limited

INDUSTRY

collaborator

Axis Clinical Trials

OTHER

lead

Acrotech Biopharma Inc.

INDUSTRY

NCT02680795 - Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | Biotech Hunter | Biotech Hunter